Sign in
Taking peoplePhase 1

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

Key facts

Who runs it
The First Affiliated Hospital of Air Force Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
5 people, planned
Started
8 Dec 2025
Expected to end
31 Jul 2028
Type of study
Interventional
Treatments tested
  • All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
Record updated
24 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Confirmed as primary membranous nephropathy (PMN) by renal biopsy
  • Classified as moderate-risk or high-risk refractory membranous nephropathy (rMN)
  • Moderate-risk rMN is defined as: eGFR ≥ 90 ml/min/1.73m² AND 24-hour urinary protein > 3.5g/d, with a reduction of no more than 50% within 6 months of receiving renin-angiotensin system inhibitor (RASi) therapy
  • High-risk rMN is defined as meeting one of the following:; eGFR < 60 ml/min/1.73m² and/or persistent proteinuria > 8g/d for more than 6 months; Normal eGFR with proteinuria > 3.5g/d and ≤50% reduction after 6 months of RASi therapy, PLUS at least one of the following: Serum albumin < 25g/L; PLA2R antibody > 50 RU/mL; Urinary α1-microglobulin > 40 μg/min; Urinary IgG > 1 μg/min; Urinary β2-microglobulin > 250 mg/d; IgG/albumin clearance ratio > 0.20
  • Diagnosis of rMN requires failure of adequate first-line immunosuppressive therapy (≥6 months of steroids+cyclophosphamide, CNI, or rituximab), defined by any of the following: persistent high-titer anti-PLA2R antibody; for antibody-negative patients, persistent nephrotic syndrome (protein >3.5g/d, albumin <30g/L); <50% reduction in proteinuria
  • Age ≥ 18 years
  • Adequate organ function, defined as:; Renal: eGFR ≥ 30 ml/min/1.73m²; Hepatic: ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN; Cardiac: LVEF ≥ 50%; NYHA Class I or II; No significant arrhythmias requiring intervention; No major cardiovascular events within the past 6 months; Respiratory: SpO2 > 92% on room air
  • Ability to understand and willingness to sign an Informed Consent Form

Who cannot take part

  • Specific treatment history or plans, including:; Prior receipt of any cell therapy (e.g., MSCs, HSCT); Major surgery within 24 weeks before or planned within 24 weeks after enrollment; Planned kidney transplantation within 3 years; History of substance abuse
  • Participation in another interventional clinical trial within 3 months prior to enrollment
  • Secondary membranous nephropathy (e.g., due to SLE, malignancy, drugs, infection)
  • Active infection requiring IV antibiotics, active tuberculosis, or positive viral serology indicating active infection, including:; HBV: HBsAg (+) and/or HBcAb (+) with detectable HBV DNA; HCV: HCV Ab (+) with detectable HCV RNA; HIV Ab (+); Active EBV or CMV infection (IgM+ or DNA above normal); Positive syphilis (Treponema pallidum) antibody (requires evaluation for active infection)
  • History of malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or thyroid cancer
  • Inability to understand the study or provide informed consent (e.g., severe dementia, mental illness)
  • Any other condition deemed by the investigator to increase risk, interfere with assessment, or affect compliance
  • Severe uncontrolled comorbidities, including:; Uncontrolled hypertension (persistent SBP > 160 mmHg or DBP > 100 mmHg); Uncontrolled diabetes (HbA1c > 8% or random glucose ≥11.1 mmol/L) or diabetic nephropathy; Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months; Active peptic ulcer or gastrointestinal bleeding within the past 6 months; Severe congenital or acquired immunodeficiency; Severe CNS diseases (e.g., catastrophic APS, uncontrolled epilepsy); End-stage organ failure not attributable to PMN
  • Pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.

Read full original descriptionShow less

Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells/kg.

In the subsequent 2 weeks, patients will be hospitalized for monitoring of vital signs and adverse reactions. The planned follow-up duration of this study is 1 years.

The group in the trial

  • To preliminarily evaluate the safety and efficacy of CD19 CAR-T in refractory membranous nephropathyOther group

    Treatment: All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy
Record updated
24 December 2025